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The orchestration of gene-expression programs is essential for cellular homeostasis.
Epigenetic processes provide to the cell a key mechanism that allows the regulation
of gene-expression networks in response to environmental stimuli. Recently epigenetic
mechanisms such as histone-modifications have been implicated with cognitive
function and altered epigenome plasticity has been linked to the pathogenesis of
neurodegenerative and neuropsychiatric diseases. Thus, key regulators of epigenetic
gene-expression have emerged as novel drug targets for brain diseases. Numerous recent
review articles discuss in detail the current findings of epigenetic processes in brain
diseases. The aim of this article is not to give yet another comprehensive overview of
the field but to specifically address the question why the same epigenetic therapies that
target histone-acetylation may be suitable to treat seemingly different diseases such as
Alzheimer’s disease and post-traumatic stress disorder.
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INTRODUCTION
The term epigenetics has been introduced by ConradWaddington
to describe heritable changes of a phenotype that does not depend
on altered DNA-sequence (Holliday, 1994). The key epigenet-
ics mechanisms are histone-modifications and DNAmethylation.
In addition to DNA-methylation it was recently discovered that
DNA can be hydroxymethylated which is particularly promi-
nent in brain tissue. Also the action of non-coding RNAs has
been considered as an epigenetic process. Histone-modifications,
DNA-methylation and non-coding RNAs act in concert to orches-
trate gene-expression in the context of gene-environment inter-
actions. Because complex neuropsychiatric diseases result from
variable combination of genetic and environmental risk factors,
epigenetic processes are gaining increasing interest in the neu-
rosciences. Numerous review articles have addressed this issue
(Abel and Zukin, 2008; Day and Sweatt, 2010; Fischer et al., 2010;
Jakovcevski and Akbarian, 2012; Parkel et al., 2013; Rudenko and
Tsai, 2014). Thus, the aim of this review is to give an overview
specifically on the role of histone-modifications in neuropsy-
chiatric diseases and ask the question why epigenetic therapies
appear to be suitable for apparently different types of brain dis-
eases, especially Alzheimer’s disease (AD) and post-traumatic
stress disorder (PTSD).
The DNA strand within a cell is tightly condensed which is
achieved by compacting DNA into chromatin that consists of
DNA bound to histone proteins. The 4 core histones (H) build
the nucleosome around with 147 bp of DNA is wrapped. The his-
tone tails are subjected to post-translational modification includ-
ing acetylation, methylation, phosphorylated, ubiquitination,
sumoylation, or ADP-ribosylation (Vaquero et al., 2003) which
is mediated by the counteracting activities of enzymes that
add or remove such modifications. As such, histone-acetylation
is mediated by Histone-acetyltransferases (HAT) and Histone-
deacetylases (HDACs). The activity of such enzymes affects the
chromatin state and thus gene-expression. On one hand the mod-
ification of histone-tails alters the electrostatic interaction of DNA
and the nucleosome and in addition the various combinations
of histone-modifications give rise to a combinatorial pattern, the
so called the “histone-code” (Strahl and Allis, 2000). Histone-
acetylation and histone-methylation occurs predominantly at
lysine residues (K). While only one acetyl group can be added to a
given lysine within a histone tail, methylation can occur asmono-,
di-, or tri-methylation. Specific histone-modifications have been
linked to a particular mode of gene-expression (Allis et al., 2007).
For example H3 that is tri-methylated at lysine (K) 4 (H3K4me3)
is amark for active genes while H3K9me3marks heterochromatin
linked to inactive genes. The role of such histone-modifications
and the corresponding enzymes are well studied in developmen-
tal processes but have more recently also be linked to cognitive
function.
HISTONE-ACETYLATION IN MEMORY CONSOLIDATION
Histone-acetylation has been linked to learning process in rodents
already in 1979 when it was found that memory training alters
the incorporation of 14C-acetate to histones in different brain
regions (Schmitt and Matthies, 1979). Mechanistic proof that
histone-acetylation is required for proper memory function was
then later demonstrated by the fact that mice which lack HAT
activity show impaired memory function (Alarcon et al., 2004;
Korzus et al., 2004; Wood et al., 2006; Oliveira et al., 2007; Vecsey
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et al., 2007; Maurice et al., 2008; Chen et al., 2010; Barrett et al.,
2011; McNulty et al., 2012). The very first studies investigated
the role of cAMP response element binding protein (CBP) and
found that mice which express a mutant form of CBP that lacks
the histone-transferase activity (Korzus et al., 2004) or lack the
complete CBP gene (Alarcon et al., 2004) show impaired memory
formation. This phenotype can be rescued by the administra-
tion of HDAC inhibitors (Alarcon et al., 2004). At least 18 HATs
are known in mammals and they are subdivided into the GNAT
(Gcn5 N-acetyltransferases) family, the MYST (MOZ, Ybf2/Sas3,
Sas2, TIP60) family, the p300/CBP family and several other HATs
do not belong to any of these families (Allis et al., 2007; Lee and
Workman, 2007). Since HATs also acetylate other proteins than
histones, a new nomenclature has been suggested and HATs are
now referred to as K-lysine acetyltransferases (KATs) followed by
a specific number. A substantial amount of data documents a role
for KAT3A/CBP inmemory function (Alarcon et al., 2004; Korzus
et al., 2004; Wood et al., 2006; Vecsey et al., 2007; Chen et al.,
2010; McNulty et al., 2012). Moreover, a role for KAT2B/PCAF
(Maurice et al., 2008) and KAT3B/P300 in memory function has
been suggested. However, the role of the other HATs remains still
unknown.
In line with the unanimous findings that impairing HAT func-
tion impairs memory formation, it was found that administration
of HDAC inhibitors to rodents improves memory consolidation
(Levenson et al., 2004; Fischer et al., 2007; Vecsey et al., 2007).
Data derived from knock-out mice were able to link such effects
to particular HDAC proteins. As such mice that lack neuronal
HDAC2 or HDAC3 show better learning than the correspond-
ing wild type littermates (Guan et al., 2009; McQuown et al.,
2011). Mice that lack neuronal HDAC1 from early developmental
stages do not show altered learning ability in the fear condition-
ing and water maze paradigms (Guan et al., 2009). However,
HDAC1 was found to be essential for fear extinction, a learn-
ing process that is critical for the treatment of emotional diseases
such as post-traumatic stress disorder (Bahari-Javan et al., 2012).
As such, increasing HDAC1 levels in the hippocampus of mice
improved fear extinction (Bahari-Javan et al., 2012). Interestingly,
the opposite is true for HDAC2 since reducing HDAC2 functions
was found to facilitate fear extinction learning in mice (Morris
et al., 2013). As for the class II HDACs, deletion of HDAC4 was
found to improve memory function in C. elegans (Wang et al.,
2011). In contrast, mice that lack HDAC4 show impaired mem-
ory function and synaptic plasticity (Kim et al., 2012; Sando et al.,
2012).Moreover, reducedHDAC4 levels have been linked tomen-
tal retardation in humans (Williams et al., 2010). Deletion of
HDAC5 in 2-month old mice does not cause memory impair-
ments (Kim et al., 2012). However, aged 10-month old HDAC5
knock-out mice develop mild memory disturbances when com-
pared to age-matched control mice (Agis-Balboa et al., 2013).
Mice that lack HDAC6 do not show significant differences in the
fear conditioning or water maze paradigm (Govindarajan et al.,
2013) and nothing is currently known for the remaining HDACs.
Naturally, the role of HATs and HDACs has been linked to
chromatin plasticity and gene-expression. In fact for most of
the above described studies, altered memory performance cor-
related with changes in gene-expression and histone-acetylation.
Nevertheless, such findings have to be interpreted with caution
since in most cases bulk changes in histone-acetylation were
measured and only selected genes were tested for expression or
studied via chromatin-immunoprecipitation (ChIP). The mecha-
nistic insight from such data is limited. More recently, researchers
have started to study histone-acetylation during memory for-
mation via ChIP-sequencing which allows for a genome-wide
analysis. For example, the levels of H4K12 acetylation in the cod-
ing region of learning-induced hippocampal genes were linked
to better memory performance in young when compared to
old mice (Peleg et al., 2010). Another recent study used ChIP-
sequencing to study H4K5 acetylation after fear conditioning
(Park et al., 2013). Nevertheless, HATs and HDACs likely regulate
memory processes also by affecting non-histone proteins, includ-
ing transcription factors (Lopez-Atalaya et al., 2013). Another
issue is that all of the above described studies analyzed brain tis-
sue that contains multiple cell types such as post-mitotic neurons,
glia cells and the endothelian cells of the blood vessels. To achieve
cell type specificity will be a key issue for future research. While,
clearly more research is needed to further understand the role of
histone-acetylation inmemory function, the current data demon-
strate a key role of HATs andHDACs in orchestrating the interplay
of synaptic and nuclear plasticity during the encoding of new
memories.
HISTONE-ACETYLATION IN BRAIN IN DISEASE
ALZHEIMER’S DISEASE
Alzheimer’s disease is the most common form of dementia in
the elderly. On the pathological background of amyloid plaques,
neurofibrillary tangles (NFTs) and neuronal cell death patients
develop memory disturbances and eventually lose the abil-
ity of managing the daily life. A small number of AD cases
(ca. 5%) is caused by mutations in amyloid precursor protein
(APP) gene or the genes that mediate its processing (familial
AD). As a consequence the brain produces more of the AD-
associated amyloid-beta 42 (Aß42) peptide (Haass and Selkoe,
2007) that is believed to form toxic oligomers, cause mem-
ory disturbances and eventually aggregates into amyloid plaques
(Palop and Mucke, 2010; Goate and Hardy, 2012). The major-
ity of the AD cases (95%) are sporadic and characterized by
a late onset. Elevated Aß42 levels, amyloid plaques and NFTs
are also observed in the sporadic form of AD albeit patients do
not carry any of the mutations characteristic for familial AD.
It has to be mentioned though that amyloid and NFT pathol-
ogy does not always correlate with cognitive decline (Snowdon
et al., 1997). In fact, while almost all research in the past was
focused on amyloid deposition, the corresponding therapeutic
clinical approaches failed (Mangialasche et al., 2010). This is cer-
tainly also due to the fact that amyloid deposition may begin at
least 20 years before the onset of clinical symptoms (Bateman
et al., 2012). As such, the tested drugs were probably given to
late. However, one should also consider the fact that most of
the tested drugs were developed for the 5% familial AD cases
but eventually given to sporadic AD patients. Novel therapeu-
tic approaches take this into consideration. For example in an
on-going clinical trial an antibody that should lower amyloid
pathology is tested in a cohort of familial AD cases (Crenezumab,
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Genentech, Roche Holding AG). Such approaches are promis-
ing but it is not clear if they are also suitable for the 95% of
patients that suffer from the sporadic form of AD. Especially since
sporadic AD is most likely a result of variable combination of
genetic and environmental risk factors it is interesting to consider
epigenetic therapeutic approaches in addition, since epigenetic
mechanisms including histone-acetylation are key mediators of
genome-environment interactions. In fact, to study the role of
epigenetics as biomarker and therapeutic targets is a growing field
of research.
Taking into account the role of histone-acetylation in mem-
ory function and especially the finding that HDAC inhibitors
can enhance memory encoding in mice, the potential of HDAC
inhibitors for cognitive diseases was soon recognized. In one of
the first studies it was found that 4 weeks intra-peritoneal (ip)
administration of the HDAC inhibitor sodium butyrate rein-
states cognitive function and synaptic plasticity in a mouse model
that allowed forebrain-specific and inducible overexpression of
the p25 protein (CK-p25 mice) (Fischer et al., 2007). P25 is a
subunit of the Cyclin-dependent kinase 5 (CDK5) that is ele-
vated in human AD patients (Patrick et al., 1999) and has been
linked to amyloid and tau pathology as well as severe neurode-
generation and memory impairment (Cruz et al., 2003, 2006;
Fischer et al., 2005). Importantly, the CK-p25 model is not based
on familial AD and sodium butyrate treatment is also effec-
tive when administered after the onset of neuronal cell death
(Fischer et al., 2007). Subsequent studies confirmed the therapeu-
tic potential of HDAC inhibitors in animal models for amyloid
deposition. Different treatment protocols and HDAC inhibitors
such as trichostatin A (Francis et al., 2009), phenylbutyrate
(Ricobaraza et al., 2009, 2010) valproate (Depakote) or suberoy-
lanilide hydroxamic acid (SAHA, Vorinostat) were used (Kilgore
et al., 2010). One study was able to demonstrate that prolonged
oral administration of sodium butyrate reinstated memory func-
tion in an amyloid-based AD model even when administered at
a stage of severe pathology (Govindarajan et al., 2011). While
all of these studies showed enhanced memory function in AD
mouse models for amyloid deposition, it is interesting to note
that none of them reported altered amyloid deposition. A recent
study employed an experimental setting in which APPPS1-21
mice orally received the HDAC inhibitor MS-275 (Entinostat)
and report reduced neuroinflammation and amyloid plaque load
(Zhang and Schluesener, 2013). Memory function was however
not tested in this study. Reduced amyloid pathology is also seen
in 3xTG AD mice—that develop amyloid and Tau-pathology—
that received a novel class II HDAC inhibitor (Sung et al.,
2013).
While such studies are encouraging, most of them tested the
therapeutic effect of targeting HDACs in models for familial AD.
Aging is the most significant risk factor for sporadic AD. It is thus
important to note that HDAC inhibitors can reinstate memory
function in mice that suffer from age-associated memory loss.
For example it was found that SAHA reinstates memory function
in old mice. This is mechanistically linked to increased H4K12
acetylation along the coding regions of learning-induced genes
(Peleg et al., 2010). Similarly, memory improvement is observed
in aged rats treated with sodium butyrate (Reolon et al., 2011)
and in senescence-accelerated prone (SAMP8) mice—amodel for
accelerated aging (Fontán-Lozano et al., 2008).
An important issue is that all of the HDAC inhibitors used so
far affect multiple HDAC proteins. To understand which of the
11 HDAC proteins would be the most suitable drug target and
which not is therefore of utmost importance. The most conclu-
sive approach to address this issue would be to cross mice that
lack a specific HDAC protein to mouse models for AD. Such data
is at present only available for the class II HDACs, HDAC5 and
HDAC6. When mice lacking HDAC5 are crossed to APPPS1-21
mice, memory function is even further impaired (Agis-Balboa
et al., 2013). Mice that lack HDAC6 do not show any obvious
phenotype. Crossing HDAC6 knock-out mice with APPPS1-21
mice restores memory function without lowering amyloid depo-
sition (Govindarajan et al., 2013). Reducing HDAC6 levels is
mechanistically linked to tubulin-acetylation and improvedmito-
chondria transport (Govindarajan et al., 2013). Moreover, reduc-
ing HDAC2 in a mouse model for amyloid deposition via RNA
interference also improves memory function and synaptic plas-
ticity (Gräff et al., 2012). Thus, at present it appears that HDAC2
and HDAC6 are the most suitable drug targets to treat memory
impairment in AD, while inhibition of HDAC5 should be avoided.
Taking into account that deletion of HDAC4 impairs memory
function in mice (Kim et al., 2012; Sando et al., 2012), inhibition
of this HDAC should also be avoided.
Since HDAC inhibitors improve memory function in AD
mouse models, HAT activators should have similar effects.
Indeed, recent data shows that administration of HAT agonists
improve memory function in wild type mice (Selvi et al., 2010;
Chatterjee et al., 2013; Schneider et al., 2013) but data for disease
models are not yet available.
In addition to the question which HDAC or HAT would be
the best drug target, an important issue to solve is if such a
therapeutic approach is disease-modifying or not. Clearly more
research is needed to clarify this issue and to elucidate if changes
in histone-acetylation are cause or consequence in AD.
In this context it is interesting to note that targeting histone-
acetylation has not only been linked to AD but also more gen-
erally to brain diseases associated with cognitive dysfunction
such as drug addiction or schizophrenia (Kumar et al., 2005;
Kim et al., 2010; Host et al., 2011; Jordi et al., 2013). We have
previously hypothesized that epigenetic processes such as histone-
modifications integrate the various environmental stimuli on the
level of altered gene-expression and thus provide an important
mechanistic link between neuronal activity and adaptive changes
in gene-expression that are critical for memory consolidation
(Sananbenesi and Fischer, 2009). In this scenario memory con-
solidation initiates a learning related epigenetic change in the
relevant brain cells. In turn, the variable combinations of genetic
and environmental risk factors for AD drive a disease-specific
epigenetic signature that contributes to pathogenesis. Therefore,
an epigenetic therapeutic approach might be beneficial since it
would act at the bottleneck where risk factors integrate and drive
pathology (Figure 1). The environmental and genetic risk factors
for different brain diseases overlap to some extent and we specu-
late that the different brain diseases reflect endpoints of epigenetic
states. This would also imply that the epigenome provides is a link
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FIGURE 1 | Complex neuropsychiatric diseases are caused by variable
combination of genetic and environmental risk factors that vary on an
individual basis and for a given disease. Epigenetic processes are key
regulatory processes that orchestrate genome-environment interactions
and there is a substantial amount of literature demonstrating a role for
epigenetics in numerous brain diseases. Thus, we speculate that disease
pathogenesis is accompanied by a specific epigenetic signature that
contributes to the deregulation of cellular homeostasis. The epigenome
therefore acts as a bottleneck and provides a bona fide drug target since it
may act disease modifying without targeting—or even knowing—all
upstream disease causing factors. The signatures are likely to differ for
different diseases in that they reflect specific de-regulation of the
corresponding enzymatic machinery. One example is the finding that
HDAC1 and HDAC2 appear to regulate distinct cellular mechanisms and
thus play different roles in the pathogenesis of PTSD and AD.
between apparently different brain diseases and we will discuss
this idea for AD and post-traumatic stress disorder (PTSD).
HISTONE-ACETYLATION IN POST-TRAUMATIC STRESS
DISORDER. A LINK TO AD?
Emotional disorders often involve excessive fear and anxiety and
therapeutic approaches involve inhibition of fear through cog-
nitive behavioral therapy. For example patients that suffer from
phobia such as fear of heights would be repeatedly exposed
to the frightening stimuli and thereby experiencing habituation
and learn that the frightening stimulus is harmless (Deacon and
Abramowitz, 2004; Ressler et al., 2004; Fischer and Tsai, 2008).
Similar therapeutic strategies are used to treat patients with
posttraumatic stress disorder (PTSD). PTSD can develop as a
result of a terrifying and traumatic event, which could involve
physical harm or was experienced as extremely threatening
(Fischer and Tsai, 2008). Patients suffering from PTSD display
extreme traumatic stress to an extent in which normal psycholog-
ical defense mechanisms fail. Symptoms may involve persistent
re-experience of the traumatic event, impairment of social inter-
action and aversive behaviors such as self-injury. When patients
are repeatedly confronted with their feared memories and at the
same time experience a feeling of safety, over time this proce-
dure can lead to reduced anxiety and aversive behavior associated
with the fear memory (Adshead, 2000; Bisson and Andrew, 2007;
Fischer and Tsai, 2008). This process is called fear extinction and
substantial progress has been made to understand the underly-
ing molecular mechanisms (Sotres-Bayon et al., 2006; Myers and
Davis, 2007; Sananbenesi et al., 2007; Fischer and Tsai, 2008).
For the context of this review article it is interesting to note that
recently histone-acetylation has been linked to fear extinction.
Thus it was found that successful fear extinction correlates with
increased H4 acetylation of the BDNF promoter in the prefrontal
cortex of mice, which results in enhanced BDNF expression.
Moreover administration of the pan-HDAC inhibitor valproate
facilitates fear extinction (Bredy et al., 2007; Bredy and Barad,
2008; Heinrichs et al., 2013). In line with such observations
i.p. injection of sodium butyrate and intrahippocampal injec-
tions of trichostatin A facilitates fear extinction in mice (Lattal
et al., 2007). Moreover, administration of SAHA facilitates fear
extinction in naive rats (Fujita et al., 2012) and also in rats
that had been exposed to the single prolonged stress paradigm,
a model for PTSD (Ponomarev et al., 2010; Matsumoto et al.,
2013). In contrast to the commonly used C57BL6J mouse it
was demonstrated that 129S1/SvlmJ mice are unable to extinct
fear memories. However, administration of the HDAC inhibitor
valporates promoted extinction in 129S1/SvlmJ (Whittle et al.,
2013). Thus, there is substantial data suggesting that HDAC
inhibitor treatment facilitates fear extinction and may provide a
novel therapeutic avenue to treat PTSD (Maddox et al., 2013).
The role of the HATs and HDACs that orchestrate fear extinc-
tion learning remains to be elucidated but it was found that
mice which lack HDAC2 display enhanced extinction learning of
cued fear and conditioned taste aversion memories (Morris et al.,
2013).
This data suggest that—similar to its role in memory
consolidation—HDAC2 improves extinction learning. In con-
trast HDAC1 was found to be essential for fear extinction. Thus
virus-mediated neuronal overexpression of HDAC1 in the dorsal
hippocampus of adult mice significantly facilitated the extinction
of contextual fear memories but did not alter other cognitive abil-
ities such as spatial memory, associative memory and working
memory (Bahari-Javan et al., 2012).
Successful extinction of fear memories required HDAC1medi-
ated repression of immediate early gene such as c-fos and egr-2
that was achieved via decreased Histone H3 Lysine 9 (H3K9)
acetylation, a marker for transcriptional activation (Kouzarides,
2007) and subsequent H3K9 trimethylation (H3K9me3), a
marker for heterochromatin. In line with this data knock down
of HDAC1 prevented transcriptional repression of c-fos and egr-2
resulting in impaired fear extinction. This data suggests that
histone-acetylation is a critical regulatory process of fear extinc-
tion. However it will be critical to elucidate the role of the relevant
enzymes and define the histone-acetylation patters for the rele-
vant genes. Especially since HDAC1 and HDAC2 appear to have
opposing roles in fear extinction. This is however also true for
AD, where HDAC2 but not HDAC1 inhibition is able to reinstate
memory function (Guan et al., 2009; Gräff et al., 2012).
In conclusion there is substantial evidence that the mecha-
nisms that orchestrate histone-acetylation are involved in fear
extinction and there is indeed further data suggesting a role of epi-
genetic mechanisms in the pathogenesis of PTSD (Zovkic et al.,
2013). Especially risk factors such as early life stress have been
linked to epigenetic changes that predispose an individual to the
development of PTSD (Domschke, 2012) and epigenetic changes
have been observed in PTSD patients (Uddin et al., 2010; Lee
et al., 2011; Rusiecki et al., 2012). Interestingly, individuals that
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suffer from PTSD at young age, have almost double the risk to
develop AD at old age (Yaffe et al., 2010; Burri et al., 2013). On the
basis of such data, we hypothesize that the pathogenesis of PTSD
correlates with epigenetic changes that contribute to disease phe-
notypes. Albeit this would need to be studied in greater detail,
there is substantial evidence that the epigenome undergoes fur-
ther changes during aging which contribute to memory decline.
Thus, the epigenome of an individual that suffered from PTSD
would be more susceptible to further age-related changes—or
other risk factors for AD—which increases the risk to eventually
develop dementia (Figure 1).
CONCLUSION
The epigenome transfers environmental stimuli into long term
adaptive changes and thus provides to neurons a mechanisms
that allows for the compromise between stability and flexibility.
Epigenetic changes have been observed in various brain diseases
and epigenetic drugs such as HDAC inhibitors show beneficial
effects in animal models for apparently different brain diseases
such as AD or PTSD. Interestingly, epidemiological data links
early life psychiatric diseases such as PTSD to late onset AD.
One common feature amongst such diseases is that they are asso-
ciated with epigenetic alterations and it can be speculated that
disease associated epigenetic changes—if not treated—predispose
the system for further de-regulation in response to additional
environmental risk factors. Thus, the various brain diseases may
be viewed as different places in the epigenetic landscape that are
off the main path but still interlinked. Epigenetic changes can
be transient, long-lasting or even transmitted across generations
but they are always reversible and thus hold great potential for
future therapeutic approaches that aim to treat the correct patient
population for a given disease.
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